Early-Phase Oncology ePRO Solution: Complete Tolerability Assessment

Targeted treatments often show efficacy below maximum tolerated dose—making the patient perspective vital for characterizing dose-tolerability relationships and selecting optimal doses for later phases. Tolerability evidence is incomplete without patient-reported adverse events data.

Signant's Pre-Configured ePRO Solution Delivers:

✓ Rapid out-of-the-box implementation for early-phase speed requirements
✓ Comprehensive tolerability assessment with validated PRO-CTCAE measures (78 AEs) plus impact assessments
✓ Frequent assessment schedules for complete insights
✓ BYOD efficiencies with provisioned device options
✓ Real-time compliance monitoring to ensure complete datasets

Key Advantages Over Paper:

• Assured data quality with timely completion tracking
• Remote patient oversight between clinic visits
• Simplified navigation through complex PRO-CTCAE
• Electronic free-text capture reduces data management burden
• Competitively priced for early-phase budgets

Purpose-built for the speed and accuracy early-phase oncology research demands.